201 related articles for article (PubMed ID: 31632140)
1. Prognostic Usefulness Of Advanced Lung Cancer Inflammation Index In Locally-Advanced Pancreatic Carcinoma Patients Treated With Radical Chemoradiotherapy.
Topkan E; Mertsoylu H; Ozdemir Y; Sezer A; Kucuk A; Besen AA; Ozyilkan O; Selek U
Cancer Manag Res; 2019; 11():8807-8815. PubMed ID: 31632140
[TBL] [Abstract][Full Text] [Related]
2. Low Systemic Inflammation Response Index Predicts Good Prognosis in Locally Advanced Pancreatic Carcinoma Patients Treated with Concurrent Chemoradiotherapy.
Topkan E; Mertsoylu H; Kucuk A; Besen AA; Sezer A; Sezen D; Bolukbasi Y; Selek U; Pehlivan B
Gastroenterol Res Pract; 2020; 2020():5701949. PubMed ID: 32802045
[TBL] [Abstract][Full Text] [Related]
3. Low Advanced Lung Cancer Inflammation Index Predicts Poor Prognosis in Locally Advanced Nasopharyngeal Carcinoma Patients Treated with Definitive Concurrent Chemoradiotherapy.
Topkan E; Ozdemir Y; Kucuk A; Guler OC; Sezer A; Besen AA; Mertsoylu H; Senyurek S; Kilic Durankus N; Bolukbasi Y; Selek U; Pehlivan B
J Oncol; 2020; 2020():3127275. PubMed ID: 33082783
[TBL] [Abstract][Full Text] [Related]
4. Baseline Low Prognostic Nutritional Index Predicts Poor Survival in Locally Advanced Nasopharyngeal Carcinomas Treated With Radical Concurrent Chemoradiotherapy.
Topkan E; Yucel Ekici N; Ozdemir Y; Besen AA; Mertsoylu H; Sezer A; Selek U
Ear Nose Throat J; 2021 Feb; 100(2):NP69-NP76. PubMed ID: 31184210
[TBL] [Abstract][Full Text] [Related]
5. High Pretreatment Platelet-to-Albumin Ratio Predicts Poor Survival Results in Locally Advanced Nasopharyngeal Cancers Treated with Chemoradiotherapy.
Haksoyler V; Topkan E
Ther Clin Risk Manag; 2021; 17():691-700. PubMed ID: 34262282
[TBL] [Abstract][Full Text] [Related]
6. High Measures of Pre-Chemoradiotherapy Platelet-to-Albumin Ratio Indicates Poor Prognosis in Locally Advanced Pancreatic Cancer Patients.
Kucuk A; Topkan E; Selek U; Haksoyler V; Mertsoylu H; Besen AA; Pehlivan B
Ther Clin Risk Manag; 2022; 18():421-428. PubMed ID: 35444422
[TBL] [Abstract][Full Text] [Related]
7. The Prognostic Significance of Novel Pancreas Cancer Prognostic Index in Unresectable Locally Advanced Pancreas Cancers Treated with Definitive Concurrent Chemoradiotherapy.
Topkan E; Selek U; Pehlivan B; Kucuk A; Haksoyler V; Kilic Durankus N; Sezen D; Bolukbasi Y
J Inflamm Res; 2021; 14():4433-4444. PubMed ID: 34511977
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Utility of Prechemoradiotherapy Albumin-to-Alkaline Phosphatase Ratio in Unresectable Locally Advanced Pancreatic Carcinoma Patients.
Haksoyler V; Topkan E
Gastroenterol Res Pract; 2021; 2021():6647145. PubMed ID: 33927759
[TBL] [Abstract][Full Text] [Related]
9. Concurrent Chemoradiotherapy Versus Chemotherapy Alone for Unresectable Locally Advanced Pancreatic Cancer: A Retrospective Cohort Study.
Choi Y; Oh DY; Kim K; Chie EK; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Ha SW; Bang YJ
Cancer Res Treat; 2016 Jul; 48(3):1045-55. PubMed ID: 26511805
[TBL] [Abstract][Full Text] [Related]
10. High pre-chemoradiotherapy pan-immune-inflammation value levels predict worse outcomes in patients with stage IIIB/C non-small-cell lung cancer.
Topkan E; Kucuk A; Ozkan EE; Ozturk D; Besen AA; Mertsoylu H; Pehlivan B; Selek U
Discov Oncol; 2023 Dec; 14(1):230. PubMed ID: 38091179
[TBL] [Abstract][Full Text] [Related]
11. Low Pre-ChemoradiotherapyPan-Immune-Inflammation Value (PIV) Measures Predict Better Survival Outcomes in Locally Advanced Pancreatic Adenocarcinomas.
Topkan E; Selek U; Kucuk A; Pehlivan B
J Inflamm Res; 2022; 15():5413-5423. PubMed ID: 36158517
[TBL] [Abstract][Full Text] [Related]
12. The effect of tumor volume and its change on survival in stage III non-small cell lung cancer treated with definitive concurrent chemoradiotherapy.
Koo TR; Moon SH; Lim YJ; Kim JY; Kim Y; Kim TH; Cho KH; Han JY; Lee YJ; Yun T; Kim HT; Lee JS
Radiat Oncol; 2014 Dec; 9():283. PubMed ID: 25498887
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of gross tumor volume delineated by FDG-PET-CT based radiotherapy treatment planning in patients with locally advanced pancreatic cancer treated with chemoradiotherapy.
Parlak C; Topkan E; Onal C; Reyhan M; Selek U
Radiat Oncol; 2012 Mar; 7():37. PubMed ID: 22429939
[TBL] [Abstract][Full Text] [Related]
14. Stereotactic Body Radiation Therapy versus Concurrent Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Propensity Score-Matched Analysis.
Shin YS; Park HH; Park JH; Seo DW; Lee SS; Yoo C; Kim S; Yoon SM; Jung J; Kim MH; Lee SK; Park DH; Song TJ; Oh D; Ryoo BY; Chang HM; Kim KP; Jeong JH; Kim JH
Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267485
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Significance of ¹⁸F-FDG Uptake in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization or Concurrent Chemoradiotherapy: A Multicenter Retrospective Cohort Study.
Lee JW; Oh JK; Chung YA; Na SJ; Hyun SH; Hong IK; Eo JS; Song BI; Kim TS; Kim DY; Kim SU; Moon DH; Lee JD; Yun M
J Nucl Med; 2016 Apr; 57(4):509-16. PubMed ID: 26742711
[TBL] [Abstract][Full Text] [Related]
16. The Prognostic Value of the Novel Global Immune-Nutrition-Inflammation Index (GINI) in Stage IIIC Non-Small Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy.
Topkan E; Selek U; Pehlivan B; Kucuk A; Ozturk D; Ozdemir BS; Besen AA; Mertsoylu H
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760482
[TBL] [Abstract][Full Text] [Related]
17. Systemic immune-inflammation index changes predict outcome in stage III non-small-cell lung cancer patients treated with concurrent chemoradiotherapy.
Huang T; Zhang H; Zhao Y; Li Y; Wang G; Zhang Y; Guo D; Ji S; Sun Z
Future Oncol; 2021 Jun; 17(17):2141-2149. PubMed ID: 33635094
[No Abstract] [Full Text] [Related]
18. Low Prognostic Nutritional Index Predicts Poor Clinical Outcomes in Patients with Stage IIIB Non-small-cell Lung Carcinoma Undergoing Chemoradiotherapy.
Ozdemir Y; Topkan E; Mertsoylu H; Selek U
Cancer Manag Res; 2020; 12():1959-1967. PubMed ID: 32214853
[TBL] [Abstract][Full Text] [Related]
19. Significance of overall concurrent chemoradiotherapy duration on survival outcomes of stage IIIB/C non-small-cell lung carcinoma patients: Analysis of 956 patients.
Topkan E; Ozdemir Y; Kucuk A; Besen AA; Mertsoylu H; Sezer A; Selek U
PLoS One; 2019; 14(7):e0218627. PubMed ID: 31329602
[TBL] [Abstract][Full Text] [Related]
20. A Nutrition-Related Factor-Based Risk Stratification for Exploring the Clinical Benefits in the Treatment of Patients With Locally Advanced Esophageal Squamous Cell Carcinoma Receiving Definitive Chemoradiotherapy: A Retrospective Cohort Study.
Yu Y; Wu H; Qiu J; Ke D; Wu Y; Lin M; Liu T; Zheng Q; Zheng H; Yang J; Wang Z; Li H; Liu L; Yao Q; Li J; Cheng W; Chen X
Front Nutr; 2022; 9():896847. PubMed ID: 35990358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
